Compare Boston Scientific Corporation (BSX) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Icl Group Ltd — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Icl Group Ltd trades at $5.01 (market cap $6.49B). The key difference: Boston Scientific Corporation is far larger — about 10.2× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.8% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ICL | |
|---|---|---|
Market Cap | $66.37B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $7.03 |
52-Week Low | $42.63 | $4.80 |
Enterprise Value | $75.94B | $9.06B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ICL trades at $4.93, up 1.65% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of $0.11, beating expectations, and maintains a dividend of $0.05. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation ratios like P/E of 23.48 and P/S of 0.86 suggest moderate pricing. Recent news highlights a $800M senior notes offering completed in June 2026.
Outlook is mixed: earnings beats and dividend yield offer support, but declining profit margins and bearish analyst consensus (100% hold) indicate caution. Key risks include raw material costs and forex headwinds, with institutional sentiment leaning neutral amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
